Now Playing
Opinion|Videos|August 27, 2024
Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Medical experts give an overview of relapsed/refractory multiple myeloma, focusing on diagnosis and current management strategies
Advertisement
Episodes in this series
Advertisement
Related to this article
Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
Dr. Wendy Harpham reflects on her journey as a physician and patient, emphasizing precise clinical communication in oncology care.
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
IMS 2026: Beth Faiman Details First Consensus Definition of Myeloma Cure
2
Shorter Postprostatectomy Radiation Matches Standard Course
3
Community Case Forum Explores Advancements and Care Collaboration in CLL
4
WCLC 2026: Katherine Kuhns Details AI, Wearables & Perioperative Care Roles
5